Results 21 to 30 of about 424 (108)
Prevention of Falls in Parkinson's Disease: Guidelines and Gaps
Movement Disorders Clinical Practice, Volume 10, Issue 10, Page 1459-1469, October 2023., 2023 ABSTRACT Background People living with Parkinson's disease (PD) have a high risk for falls. Objective To examine gaps in falls prevention targeting people with PD as part of the Task Force on Global Guidelines for Falls in Older Adults. Methods A Delphi consensus process was used to identify specific recommendations for falls in PD.
Richard Camicioli +7 more
wiley +1 more source
Prospects for Droxidopa in Neurogenic Orthostatic Hypotension [PDF]
Hypertension, 2015 See related article, pp 101–107 Neurogenic orthostatic hypotension (nOH) is a debilitating disorder defined by a sustained decrease in systolic blood pressure of 20 mm Hg or in diastolic blood pressure of 10 mm Hg within 3 minutes of head-up tilt or standing.1 The disorder is associated with attenuated increases in plasma norepinephrine and peripheral
Julian M. Stewart, Amanda J. Ross
openaire +3 more sources
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
British Journal of Pharmacology, Volume 180, Issue S2, Page S23-S144, October 2023., 2023 The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and about 6000 interactions with about 3900 ligands.
Stephen P. H. Alexander +165 more
wiley +1 more source
Psychogeriatrics, Volume 23, Issue 5, Page 752-762, September 2023., 2023 Background The real‐world status of satisfaction with medication for dementia with Lewy bodies (DLB) has not been elucidated. We assessed the satisfaction of patients with DLB, their caregivers, and their attending physicians (trios) with medication according to the clinical symptom domains of DLB.
Shunji Toya +4 more
wiley +1 more source
Accelerated approval drug labels often lack information for clinical decision‐making
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 43, Issue 4, Page 300-304, April 2023., 2023 Abstract Study objective We evaluated US Food and Drug Administration labels for drugs approved under the accelerated approval pathway and whether these labels contained in sufficient information regarding their accelerated approval. Design Retrospective, observational, cohort study.
Jeromie Ballreich +5 more
wiley +1 more source
Differences in Parkinson's disease treatment between neurology and other departments in Japan
Neurology and Clinical Neuroscience, Volume 11, Issue 2, Page 79-89, March 2023., 2023 Abstract Background Parkinson's disease is common in elderly people and is treated in the neurology department as well as in other departments. Recently, treatment options for Parkinson's disease have expanded; this complicates selection of the best treatment regimen.
Yoshio Tsuboi +5 more
wiley +1 more source
Neurological Therapeutics, 2022 Introduction Droxidopa is approved to treat neurogenic orthostatic hypotension (nOH) symptoms in patients with autonomic failure based on short-term clinical trial data. Additional data on the long-term efficacy of droxidopa are needed. We have evaluated
R. Hauser +6 more
semanticscholar +1 more source
Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 9, Issue 1, January‐March 2023., 2023 Abstract The regulatory path for drug approval is increasingly well defined. Drugs for the treatment of Alzheimer disease (AD) need to show statistically significant benefit over placebo with respect to cognitive and functional measures, with the Clinical Dementia Rating scale and Alzheimer's Disease Assessment Scale–Cognitive Subscale being among the ...
Marwan N. Sabbagh +9 more
wiley +1 more source
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension [PDF]
BMC Neurology, 2017 Droxidopa, a prodrug of norepinephrine, was approved for treatment of neurogenic orthostatic hypotension (nOH) due to primary autonomic disorders based on 3 randomized double-blind studies. We performed safety and efficacy analyses of this pooled dataset (n = 460).Efficacy was assessed using Orthostatic Hypotension Questionnaire (OHQ) scores (composite
L. Arthur Hewitt +3 more
openaire +4 more sources
Acta Neurologica Scandinavica, Volume 2023, Issue 1, 2023., 2023 Objectives. Postural orthostatic tachycardia syndrome (POTS) is characterized by cardiovascular autonomic dysfunction of unknown etiology with high a prevalence of gastrointestinal symptoms. The aim of the present study was to examine sociodemographic, lifestyle, and nutritional factors as well as inflammatory markers in patients with POTS.
Hanna Tufvesson +5 more
wiley +1 more source